Related Experiment Video
Updated: May 11, 2026
04:32
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Ventilator associated pneumonia: evolving definitions and preventive strategies.
Cristina Mietto1, Riccardo Pinciroli, Niti Patel
1Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Respiratory Care
|May 28, 2013
Summary
Ventilator-associated pneumonia (VAP) is a common hospital infection in intubated patients. New strategies focus on improving secretion drainage and preventing bacterial colonization to reduce VAP incidence.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Respiratory Therapy
Background:
- Ventilator-associated pneumonia (VAP) is a frequent and costly hospital-acquired infection in intubated patients, associated with increased mortality and morbidity.
- Traditional clinical diagnosis of VAP lacks accuracy and reliability, leading to discrepancies with surveillance data using objective criteria.
- The endotracheal tube (ETT) is a primary factor in VAP development, facilitating bacterial colonization and lung infection through secretion pooling and biofilm formation.
Purpose of the Study:
- To review current challenges in VAP definition and pathophysiology.
- To present novel and effective strategies for VAP prevention in intubated patients.
Main Methods:
- Review of existing literature on VAP definition, diagnosis, and pathogenesis.
- Analysis of emerging preventive strategies targeting secretion management and bacterial colonization.
- Discussion of innovations in endotracheal tube (ETT) design and adjunct devices.
Main Results:
- New definitions based on objective data have led to reported zero VAP rates, potentially due to patient selection rather than intervention effectiveness.
- Pathophysiological mechanisms of VAP involve ETT-related challenges like secretion pooling, impaired mucociliary clearance, and biofilm formation.
- Emerging preventive strategies include optimizing body positioning for secretion drainage and modifying ETTs (e.g., subglottic drainage, coated ETTs) to reduce bacterial colonization and biofilm.
Conclusions:
- Effective VAP prevention requires addressing both the definition/diagnosis and the underlying pathophysiological mechanisms.
- Innovations in ETT design and adjunct devices show promise in reducing VAP incidence by managing secretions and preventing biofilm.
- Further research and implementation of these strategies are crucial to decrease the burden of VAP in critical care settings.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps: